DrugDashboards

Ketamine Hydrochloride

Ketamine Hydrochloride · KETAMINE HYDROCHLORIDE 50 mg/mL · Injection, Solution, Concentrate · Intramuscular; Intravenous · Hospira, Inc.

NDC 00409-2053-10 · 10 VIAL, MULTI-DOSE in 1 BOX / 10 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4$0.6Dec 2025Sep 2026$0.5579
9 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$36.24
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$2,063
350 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 3 active manufacturers+10
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for ketamine hydrochloride (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

  • Hospira, Inc.United States
    analysis · label · manufacture · pack

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA074549
TE code
AP
Approval date
Jun 27, 1996
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10)Nov 7, 2025

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Ketamine Hydrochloride (Injection, Solution, Concentrate)

LabelerStrengthFirst seenLast seen
Henry Schein, Inc.KETAMINE HYDROCHLORIDE 50 mg/mLJul 15, 2026Sep 2, 2026
Hospira, Inc.KETAMINE HYDROCHLORIDE 100 mg/mLJul 15, 2026Sep 2, 2026
Hospira, Inc.KETAMINE HYDROCHLORIDE 50 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCKETAMINE HYDROCHLORIDE 100 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.KETAMINE HYDROCHLORIDE 100 mg/mLJul 15, 2026Jul 29, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ketamine Hydrochloride — NDC 00409-2053-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00409205310.

Free to cite with attribution — see how the data is put together.